Kartner N, Augustinas O, Jensen T J, Naismith A L, Riordan J R
Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.
Nat Genet. 1992 Aug;1(5):321-7. doi: 10.1038/ng0892-321.
Misprocessing and mislocalization of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) has been described for the major CF-causing mutation (delta F508) in heterologous expression systems in vitro. We have generated monoclonal antibodies (mAbs) to CFTR with the aim of localizing the protein and its CF variants in vivo. Of the tissues where CFTR was observed, only the sweat gland is readily available and does not undergo secondary changes due to CF disease pathology. Sweat ducts from CF patients homozygous for delta F508 did not show the typical apical membrane staining seen in control biopsies. This demonstrates that the biosynthetic arrest and intracellular retention of delta F508 CFTR initially observed in vitro does occur in vivo and emphasizes the need to focus efforts on understanding the mislocalization.
在体外异源表达系统中,已经描述了囊性纤维化(CF)跨膜电导调节因子(CFTR)的错误加工和错误定位与导致CF的主要突变(ΔF508)有关。我们制备了针对CFTR的单克隆抗体(mAb),目的是在体内定位该蛋白及其CF变体。在观察到CFTR的组织中,只有汗腺易于获取,并且不会因CF疾病病理而发生继发性变化。对于ΔF508纯合的CF患者的汗腺导管,未显示出对照活检中所见的典型顶膜染色。这表明最初在体外观察到的ΔF508 CFTR的生物合成停滞和细胞内滞留确实发生在体内,并强调了集中精力理解错误定位的必要性。